Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Avastin Loses Its Breast Cancer Claim; FDA’s Hamburg Opts For Withdrawal Over Restrictions

Nov 18 2011

• By Sue Sutter

Related Content

Pfizer Pulls Mylotarg For Safety 10 Years After Accelerated Approval

Jun 28 2010

Shire’s Request For <i>ProAmatine</i> Hearing Will Go Unanswered Until 2012

Oct 24 2011

Genentech Restricts Population In Last-Ditch Bid To Keep <i>Avastin</i>’s Breast Cancer Claim

Aug 08 2011

<i>Avastin</i>’s Breast Cancer Claim: Will FDA’s Hamburg Take A Middle Road?

Jul 04 2011

Genentech Losing Its Legs? <i>Avastin</i> Study Proposal Undercut By Feasibility, Scientific Concerns

Jul 11 2011

Related Companies

Genentech, Inc.

Takeda Pharmaceutical Co. Ltd.

Pfizer Inc.

AstraZeneca PLC

Additional Topics

Risk Management Drug Approval Standards BioPharmaceutical

More from Drug Safety

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window